TAK-285 N-(2-(4-((3-氯-4-[3-(三氟甲基)苯氧基)苯基)氨基)-5H-吡咯并[3,2-d]嘧啶-5-基)乙基)-3-羟基-3-甲基丁酰胺
CAS 871026-44-7 MFCD71026447
化学结构图
SMILES: CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21
化学属性
| Mol. Formula | C26H25ClF3N5O3 |
|---|---|
| Mol. Weight | 547.96 |
| Appearance | White to off-white solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | TAK-285 |
|---|---|
| Chemical Name Translation | N-(2-(4-((3-氯-4-[3-(三氟甲基)苯氧基)苯基)氨基)-5H-吡咯并[3,2-d]嘧啶-5-基)乙基)-3-羟基-3-甲基丁酰胺 |
| Chemicalbook ID | CB72621152 |
| Formula | C26H25ClF3N5O3 |
| Synonym | TAK285, TAK285, TAK 285 |
| IUPAC Name | N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide |
| InChIKey | ZYQXEVJIFYIBHZ-UHFFFAOYSA-N |
| InChI | InChI=1S/C26H25ClF3N5O3/c1-25(2,37)14-22(36)31-9-11-35-10-8-20-23(35)24(33-15-32-20)34-17-6-7-21(19(27)13-17)38-18-5-3-4-16(12-18)26(28,29)30/h3-8,10,12-13,15,37H,9,11,14H2,1-2H3,(H,31,36)(H,32,33,34) |
| Canonical SMILES | CC(C)(O)CC(NCCN1C=CC2=NC=NC(NC3=CC=C(OC4=CC=CC(C(F)(F)F)=C4)C(Cl)=C3)=C21)=O |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is currently being developed by Takeda. TAK-285 was found to be well tolerate in Phase I trials. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300 mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300 mg b.i.d. The toxicity profile and PK properties of oral TAK-285 warrant further evaluation.
